Directorio

We are doing this study to see if people have the L1 gene called apolipoprotein (APOL1) and to learn how this may affect them.

We are doing this study to see if the study drugs, domvanalimab and zimberelimab, are safe and effective for treating advanced or metastatic gastroesophageal adenocarcinoma.

If you join this study, you will be randomly placed into one of two groups. One group will get the study medicine called efgartigimod, and the other group will get a placebo, which is a fake medicine. Both are given through a tube in your vein, called an IV. You will get the medicine or placebo for the first 4 weeks. After that, depending on your platelet count, you will keep getting it every week or every other week for 20 more weeks. After 24 weeks, you may be able to join the next part of the study, where everyone gets the real medicine for up to 52 weeks. If the medicine does not work well enough after 12 weeks, you might be able to switch to the real medicine earlier.

In this study, people will be randomly chosen to get either a medicine called efgartigimod or a placebo. A placebo looks like the real medicine but does not have any medicine in it. It is used to help compare results. There is a 67% chance of getting efgartigimod and a 33% chance of getting the placebo. That means twice as many people will get the real medicine. The study will last about 1 to 2 years, depending on how each person reacts to the medicine. People will need to visit the study clinic up to 20 times for tests and check-ups.

We are doing this study to determine the safety and effectiveness of an experimental medical device called the GORE Ascending Stent Graft (ASG Device) for the treatment of aortic diseases.

We are doing this study to learn more about the effects of an experimental drug called RP1 (the study drug) for organ transplant recipients who have an advanced form of skin cancer.

We are doing this study to find out if an experimental drug called ixoberogene soroparvovec (the study drug) is a safe and effective option for people with neovascular age-related macular degeneration (wet AMD). We want to see how well it works compared to the currently approved standard treatment, Eylea® (aflibercept).